CN114867721A - 取代的直链螺环衍生物 - Google Patents
取代的直链螺环衍生物 Download PDFInfo
- Publication number
- CN114867721A CN114867721A CN202080087644.2A CN202080087644A CN114867721A CN 114867721 A CN114867721 A CN 114867721A CN 202080087644 A CN202080087644 A CN 202080087644A CN 114867721 A CN114867721 A CN 114867721A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- group
- independently selected
- compound
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410373679.2A CN118255774A (zh) | 2019-12-19 | 2020-12-17 | 取代的直链螺环衍生物 |
| CN202410373688.1A CN118344372A (zh) | 2019-12-19 | 2020-12-17 | 取代的直链螺环衍生物 |
| CN202410373672.0A CN118255773A (zh) | 2019-12-19 | 2020-12-17 | 取代的直链螺环衍生物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/126760 | 2019-12-19 | ||
| CN2019126760 | 2019-12-19 | ||
| US202062961775P | 2020-01-16 | 2020-01-16 | |
| US62/961775 | 2020-01-16 | ||
| CNPCT/CN2020/126595 | 2020-11-04 | ||
| CN2020126595 | 2020-11-04 | ||
| PCT/CN2020/137266 WO2021121327A1 (en) | 2019-12-19 | 2020-12-17 | Substituted straight chain spiro derivatives |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410373679.2A Division CN118255774A (zh) | 2019-12-19 | 2020-12-17 | 取代的直链螺环衍生物 |
| CN202410373672.0A Division CN118255773A (zh) | 2019-12-19 | 2020-12-17 | 取代的直链螺环衍生物 |
| CN202410373688.1A Division CN118344372A (zh) | 2019-12-19 | 2020-12-17 | 取代的直链螺环衍生物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114867721A true CN114867721A (zh) | 2022-08-05 |
Family
ID=76476870
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080087644.2A Pending CN114867721A (zh) | 2019-12-19 | 2020-12-17 | 取代的直链螺环衍生物 |
| CN202410373672.0A Pending CN118255773A (zh) | 2019-12-19 | 2020-12-17 | 取代的直链螺环衍生物 |
| CN202410373688.1A Pending CN118344372A (zh) | 2019-12-19 | 2020-12-17 | 取代的直链螺环衍生物 |
| CN202410373679.2A Pending CN118255774A (zh) | 2019-12-19 | 2020-12-17 | 取代的直链螺环衍生物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410373672.0A Pending CN118255773A (zh) | 2019-12-19 | 2020-12-17 | 取代的直链螺环衍生物 |
| CN202410373688.1A Pending CN118344372A (zh) | 2019-12-19 | 2020-12-17 | 取代的直链螺环衍生物 |
| CN202410373679.2A Pending CN118255774A (zh) | 2019-12-19 | 2020-12-17 | 取代的直链螺环衍生物 |
Country Status (21)
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024046457A1 (en) * | 2022-09-02 | 2024-03-07 | Hutchmed Limited | Triazine compounds and uses thereof |
| CN120365200A (zh) * | 2025-04-18 | 2025-07-25 | 北京蓝博特科技有限公司 | 一种(s)-2-(3,5-二甲基苯基)吡咯烷盐酸盐的制备方法 |
| US12473295B2 (en) | 2019-12-19 | 2025-11-18 | Janssen Pharmaceutica Nv | Substituted straight chain spiro derivatives |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL319363A (en) | 2017-01-31 | 2025-05-01 | Arvinas Operations Inc | Cervalon ligands and bifunctional compounds containing them |
| WO2021127443A1 (en) | 2019-12-19 | 2021-06-24 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| BR112023021040A2 (pt) * | 2021-05-08 | 2024-02-06 | Janssen Pharmaceutica Nv | Derivados espiro substituídos |
| EP4334310A1 (en) | 2021-05-08 | 2024-03-13 | JANSSEN Pharmaceutica NV | Substituted spiro derivatives |
| AU2022274071A1 (en) | 2021-05-11 | 2024-01-04 | Janssen Pharmaceutica Nv | Combination therapies |
| KR20240006638A (ko) | 2021-05-11 | 2024-01-15 | 얀센 파마슈티카 엔브이 | 조합 요법 |
| CA3218479A1 (en) | 2021-06-01 | 2022-12-08 | Wei Cai | Substituted phenyl-1h-pyrrolo[2, 3-c]pyridine derivatives |
| WO2022253289A1 (en) | 2021-06-03 | 2022-12-08 | Janssen Pharmaceutica Nv | Pyridazines or 1,2,4-triazines substituted by spirocyclic amines |
| AU2022292697A1 (en) * | 2021-06-17 | 2024-02-01 | Janssen Pharmaceutica Nv | (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer |
| EP4271676B1 (en) * | 2021-12-03 | 2026-07-01 | Les Laboratoires Servier | DIAZASPIRO CARBONYL SUBSTITUTE COMPOUNDS AND THEIR USE |
| US20260151399A1 (en) | 2022-11-24 | 2026-06-04 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
| KR20250170131A (ko) | 2023-04-17 | 2025-12-04 | 얀센 파마슈티카 엔브이 | 조혈 장애를 치료하기 위한 메닌-ll1 억제제, dna 삽입제 및 피리미딘 유사체의 조합물 |
| KR20260099138A (ko) | 2023-10-20 | 2026-06-26 | 얀센 파마슈티카 엔브이 | 암 치료에 사용하기 위한, (r)-n-에틸-5-플루오로-n-아이소프로필-2-((5-(2-(6-((2-메톡시에틸)(메틸)아미노)-2-메틸헥산-3-일)-2,6-다이아자스피로[3.4]옥탄-6-일)-1,2,4-트라이아진-6-일)옥시)벤즈아미드, 이의 제제 및 이의 투여 요법 |
| KR20260115654A (ko) | 2023-12-04 | 2026-07-24 | 쇼우야오 홀딩스 (베이징) 코., 엘티디. | 치환된 다환 화합물 |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05279305A (ja) * | 1992-04-02 | 1993-10-26 | Ono Pharmaceut Co Ltd | 3′−アミノ−2′−ヒドロキシアセトフェノンの製造方法 |
| CN105330698A (zh) * | 2014-07-04 | 2016-02-17 | 南京明德新药研发股份有限公司 | 螺环芳基磷氧化物和硫化物 |
| US20170275302A1 (en) * | 2014-10-14 | 2017-09-28 | Alexander Pasternak | Inhibitors of the renal outer medullary potassium channel |
| WO2018175746A1 (en) * | 2017-03-24 | 2018-09-27 | Kura Oncology, Inc. | Methods for treating hematological malignancies and ewing's sarcoma |
| US20190010167A1 (en) * | 2015-12-22 | 2019-01-10 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| WO2019060365A1 (en) * | 2017-09-20 | 2019-03-28 | Kura Oncology, Inc. | SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE |
| CN109689663A (zh) * | 2016-09-14 | 2019-04-26 | 詹森药业有限公司 | Menin-mll相互作用的螺二环抑制剂 |
| CN109743875A (zh) * | 2016-06-10 | 2019-05-10 | 生命医药公司 | Menin-mll相互作用的抑制剂 |
| WO2020069027A1 (en) * | 2018-09-26 | 2020-04-02 | Kura Oncology, Inc. | Treatment of hematological malignancies with inhibitors of menin |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| WO2003070739A1 (en) | 2002-02-19 | 2003-08-28 | Cv Therapeutics, Inc. | Partial and full agonists of a1 adenosine receptors |
| US20040043959A1 (en) | 2002-03-04 | 2004-03-04 | Bloom Laura A. | Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
| US20040138238A1 (en) | 2002-08-08 | 2004-07-15 | Dhanoa Dale S. | Substituted aminopyrimidine compounds as neurokinin antagonists |
| CA2509406C (en) | 2002-12-23 | 2012-07-03 | Janssen Pharmaceutica N.V. | Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
| US7612078B2 (en) | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| MXPA06013250A (es) | 2004-05-14 | 2007-02-28 | Abbott Lab | Inhibidores de quinasa como agentes terapeuticos. |
| JP4545196B2 (ja) | 2005-01-19 | 2010-09-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 有糸分裂キネシン阻害剤 |
| GB0713602D0 (en) | 2007-07-12 | 2007-08-22 | Syngenta Participations Ag | Chemical compounds |
| TWI389913B (zh) | 2008-09-08 | 2013-03-21 | Lg Life Sciences Ltd | 并合雜環化合物 |
| WO2010041366A1 (ja) | 2008-10-06 | 2010-04-15 | 日本電気株式会社 | 無線通信装置、無線通信システム、無線通信装置の制御方法、及び記録媒体 |
| WO2010066629A2 (en) | 2008-12-09 | 2010-06-17 | F. Hoffmann-La Roche Ag | Novel azaindoles |
| JP2011026305A (ja) | 2009-06-24 | 2011-02-10 | Daiichi Sankyo Co Ltd | イミダゾールカルボニル化合物を含有する医薬組成物 |
| CN102471291B (zh) | 2009-08-20 | 2015-04-22 | 拜尔农作物科学股份公司 | 用作杀螨剂和杀昆虫剂的3-三唑基苯基取代的硫化物衍生物 |
| AU2010289321A1 (en) | 2009-09-04 | 2012-04-05 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
| GB201004200D0 (en) * | 2010-03-15 | 2010-04-28 | Univ Basel | Spirocyclic compounds and their use as therapeutic agents and diagnostic probes |
| US9586961B2 (en) | 2010-07-09 | 2017-03-07 | Leo Pharma A/S | Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof |
| AU2011341441A1 (en) | 2010-12-03 | 2013-06-20 | Epizyme, Inc. | Modulators of histone methyltransferase, and methods of use thereof |
| EP2646454B1 (en) | 2010-12-03 | 2015-07-08 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| GB201021623D0 (en) | 2010-12-21 | 2011-02-02 | Isis Innovation | Detection of acute myeloid leukaemia |
| WO2013014162A1 (en) | 2011-07-28 | 2013-01-31 | Cellzome Limited | Heterocyclyl pyrimidine analogues as jak inhibitors |
| WO2013018404A1 (ja) | 2011-08-01 | 2013-02-07 | オリンパスメディカルシステムズ株式会社 | 挿入部形状表示装置 |
| CN103889983B (zh) | 2011-09-14 | 2015-12-09 | 普罗克西梅根有限公司 | 酶抑制剂化合物 |
| WO2014035140A2 (en) | 2012-08-30 | 2014-03-06 | Kainos Medicine, Inc. | Compounds and compositions for modulating histone methyltransferase activity |
| CN103664991B (zh) | 2012-09-19 | 2016-12-28 | 中国科学院福建物质结构研究所 | 噻吩[2,3‑d]嘧啶衍生物、其制备方法及其用途 |
| MX2015006191A (es) | 2012-11-16 | 2015-08-10 | Merck Sharp & Dohme | Inhibidores de purina de fosfatidilinositol 3-quinasa delta humana. |
| US9908887B2 (en) | 2012-12-21 | 2018-03-06 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| US9604930B2 (en) | 2012-12-21 | 2017-03-28 | Epizyme, Inc. | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof |
| JP2016505002A (ja) | 2012-12-21 | 2016-02-18 | エピザイム,インコーポレイティド | ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するprmt5阻害剤およびその使用 |
| AU2014249233A1 (en) | 2013-03-13 | 2015-09-24 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
| US10329270B2 (en) | 2013-10-21 | 2019-06-25 | Merck Patent Gmbh | Heteroaryl compounds as BTK inhibitors and uses thereof |
| US9708568B2 (en) | 2014-05-06 | 2017-07-18 | The Procter & Gamble Company | Fragrance compositions |
| US20170119769A1 (en) | 2014-06-10 | 2017-05-04 | The Trustees Of The University Of Pennsylvania | Scaffolds for inhibitors of menin-mll interactions |
| WO2015200680A2 (en) | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| JP6487527B2 (ja) * | 2014-07-04 | 2019-03-20 | チル ファーマシューティカル カンパニー リミテッド | スピロ環アリールリン酸化物及びアリールリン硫化物(spirocyclic aryl phosphorus oxide and aryl phosphorus sulfide) |
| USRE49687E1 (en) | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| GB201416352D0 (en) * | 2014-09-16 | 2014-10-29 | Shire Internat Gmbh | Spirocyclic derivatives |
| US10526341B2 (en) | 2014-11-19 | 2020-01-07 | Memorial Sloan-Kettering Cancer Center | Thienopyrimidines and uses thereof |
| PL3233857T3 (pl) | 2014-12-18 | 2020-07-27 | Takeda Pharmaceutical Company Limited | Stałe postacie skondensowanych heteroaromatycznych pirolidynonów |
| CN105732636B (zh) | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| EA031895B1 (ru) | 2015-02-24 | 2019-03-29 | Пфайзер Инк. | Замещенные нуклеозидные производные, полезные в качестве агентов против рака |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制menin及mll蛋白之交互作用的方法及組合物 |
| WO2016197027A1 (en) | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| TWI730980B (zh) | 2015-08-26 | 2021-06-21 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
| AU2017212572A1 (en) | 2016-01-26 | 2018-08-23 | Memorial Sloan-Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia |
| WO2017161028A1 (en) | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Substituted inhibitors of menin-mll and methods of use |
| US10752639B2 (en) | 2016-03-16 | 2020-08-25 | Kura Oncology, Inc. | Bridged bicyclic inhibitors of menin-MLL and methods of use |
| CN109415337B (zh) | 2016-05-02 | 2022-01-18 | 密执安大学评议会 | 作为多发性内分泌腺瘤蛋白抑制剂的哌啶 |
| WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
| WO2018024602A1 (en) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
| JP7071644B2 (ja) | 2016-09-06 | 2022-05-19 | 株式会社スリーボンド | 熱硬化型導電性接着剤 |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| TWI753016B (zh) | 2016-09-14 | 2022-01-21 | 比利時商健生藥品公司 | Menin-mll相互作用之稠合二環抑制劑 |
| CA3033239A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-mll interaction |
| CN118359610A (zh) | 2016-09-16 | 2024-07-19 | 生命医药有限责任公司 | Menin-mll相互作用的抑制剂 |
| WO2018106820A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| WO2018106818A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| KR102513564B1 (ko) | 2016-12-15 | 2023-03-22 | 얀센 파마슈티카 엔.브이. | 메닌-mll 상호작용의 아제판 억제제 |
| EA201991448A1 (ru) | 2017-01-06 | 2019-12-30 | Янссен Фармацевтика Нв | Азепановые ингибиторы взаимодействия менин-mll |
| CN108456208B (zh) | 2017-02-22 | 2021-04-16 | 广州市恒诺康医药科技有限公司 | 氮杂螺环类化合物及其制备方法和应用 |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| SG11201911859QA (en) | 2017-06-16 | 2020-01-30 | Beta Pharma Inc | Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof |
| IL271946B (en) | 2017-07-09 | 2022-09-01 | Biosight Ltd | Combination cancer therapy |
| GB201720077D0 (en) | 2017-12-01 | 2018-01-17 | Univ Oxford Innovation Ltd | Leukaemic stem cell |
| JP7307729B2 (ja) | 2017-12-20 | 2023-07-12 | ヤンセン ファーマシューティカ エヌ.ベー. | メニン-mll相互作用のエキソ-アザスピロ阻害剤 |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| TWI815954B (zh) | 2018-08-27 | 2023-09-21 | 日商住友製藥股份有限公司 | 光學活性氮雜雙環衍生物 |
| JP7594787B2 (ja) | 2018-12-07 | 2024-12-05 | ユニバーシティ オブ メリーランド、ボルチモア | 非ATP/触媒部位p38マイトジェン活性化プロテインキナーゼ阻害剤 |
| TW202104207A (zh) | 2019-04-17 | 2021-02-01 | 美商健生生物科技公司 | 二氫乳清酸脫氫酶抑制劑 |
| JP7319395B2 (ja) | 2019-06-14 | 2023-08-01 | ディスアーム セラピューティクス, インコーポレイテッド | Sarm1の阻害剤 |
| KR102924600B1 (ko) | 2019-12-18 | 2026-02-09 | 솔루스첨단소재 주식회사 | 유기 화합물 및 이를 이용한 유기 전계 발광 소자 |
| UY38988A (es) | 2019-12-19 | 2021-06-30 | Janssen Pharmaceutica Nv | Derivados espiráncos sustituidos de cadena lineal |
| CN111297863B (zh) | 2020-03-30 | 2021-06-25 | 四川大学华西医院 | menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用 |
| IL297039A (en) | 2020-04-07 | 2022-12-01 | Syndax Pharmaceuticals Inc | Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof |
| WO2022114164A1 (ja) | 2020-11-30 | 2022-06-02 | アステラス製薬株式会社 | ヘテロアリールカルボキシアミド化合物 |
| EP4334310A1 (en) | 2021-05-08 | 2024-03-13 | JANSSEN Pharmaceutica NV | Substituted spiro derivatives |
| BR112023021040A2 (pt) | 2021-05-08 | 2024-02-06 | Janssen Pharmaceutica Nv | Derivados espiro substituídos |
| AU2022274071A1 (en) | 2021-05-11 | 2024-01-04 | Janssen Pharmaceutica Nv | Combination therapies |
| KR20240006638A (ko) | 2021-05-11 | 2024-01-15 | 얀센 파마슈티카 엔브이 | 조합 요법 |
| JP2024520900A (ja) | 2021-05-12 | 2024-05-27 | シンダックス ファーマシューティカルズ, インコーポレイテッド | 癌の治療のための組合せ |
| CA3218479A1 (en) | 2021-06-01 | 2022-12-08 | Wei Cai | Substituted phenyl-1h-pyrrolo[2, 3-c]pyridine derivatives |
| WO2022253289A1 (en) | 2021-06-03 | 2022-12-08 | Janssen Pharmaceutica Nv | Pyridazines or 1,2,4-triazines substituted by spirocyclic amines |
| AU2022292697A1 (en) | 2021-06-17 | 2024-02-01 | Janssen Pharmaceutica Nv | (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer |
| EP4271676B1 (en) * | 2021-12-03 | 2026-07-01 | Les Laboratoires Servier | DIAZASPIRO CARBONYL SUBSTITUTE COMPOUNDS AND THEIR USE |
| MX2024007201A (es) | 2021-12-15 | 2024-08-06 | Dana Farber Cancer Inst Inc | Direccionamiento terapeutico del tumor del estroma gastrointestinal (gist) mediante la alteracion del complejo epigenetico de menina-mll. |
| WO2023150635A1 (en) * | 2022-02-04 | 2023-08-10 | Kura Oncology, Inc. | Treatment of hematological malignancies with menin inhibitors and p-glycoprotein inhibitors |
| CN120514709A (zh) | 2022-05-09 | 2025-08-22 | 赛达克斯制药股份有限公司 | 用于治疗癌症的menin-mll抑制剂 |
| EP4626885A1 (en) | 2022-11-30 | 2025-10-08 | Janssen Pharmaceutica NV | Cyclobutyl substituted bicyclic compounds |
| WO2024114658A1 (en) | 2022-11-30 | 2024-06-06 | Janssen Pharmaceutica Nv | Substituted 1-phenyl-3, 4-dihydropyrido [3, 4-d] pyrimidin-2-one derivatives |
| JP2025540762A (ja) | 2022-11-30 | 2025-12-16 | ヤンセン ファーマシューティカ エヌ.ベー. | メニン-mll阻害剤及びbcl-2阻害剤を含む組み合わせ |
| JP2025540759A (ja) | 2022-11-30 | 2025-12-16 | ヤンセン ファーマシューティカ エヌ.ベー. | メニン-mll阻害剤及び少なくとも1つの他の治療剤を含む組み合わせ |
| KR20250170131A (ko) | 2023-04-17 | 2025-12-04 | 얀센 파마슈티카 엔브이 | 조혈 장애를 치료하기 위한 메닌-ll1 억제제, dna 삽입제 및 피리미딘 유사체의 조합물 |
-
2020
- 2020-12-17 UY UY0001038988A patent/UY38988A/es unknown
- 2020-12-17 MX MX2022007652A patent/MX2022007652A/es unknown
- 2020-12-17 PE PE2022001149A patent/PE20230162A1/es unknown
- 2020-12-17 KR KR1020227024649A patent/KR20220118500A/ko active Pending
- 2020-12-17 US US17/604,818 patent/US12473295B2/en active Active
- 2020-12-17 CN CN202080087644.2A patent/CN114867721A/zh active Pending
- 2020-12-17 IL IL293965A patent/IL293965B1/en unknown
- 2020-12-17 CN CN202410373672.0A patent/CN118255773A/zh active Pending
- 2020-12-17 EP EP20902289.6A patent/EP4077312A4/en active Pending
- 2020-12-17 TW TW114108659A patent/TW202525813A/zh unknown
- 2020-12-17 PH PH1/2022/551502A patent/PH12022551502A1/en unknown
- 2020-12-17 AU AU2020404305A patent/AU2020404305B2/en active Active
- 2020-12-17 WO PCT/CN2020/137266 patent/WO2021121327A1/en not_active Ceased
- 2020-12-17 CN CN202410373688.1A patent/CN118344372A/zh active Pending
- 2020-12-17 UA UAA202202499A patent/UA129208C2/uk unknown
- 2020-12-17 CA CA3161045A patent/CA3161045A1/en active Pending
- 2020-12-17 CR CR20220346A patent/CR20220346A/es unknown
- 2020-12-17 JP JP2022537271A patent/JP7554829B2/ja active Active
- 2020-12-17 CN CN202410373679.2A patent/CN118255774A/zh active Pending
- 2020-12-17 TW TW109144670A patent/TWI878414B/zh active
-
2022
- 2022-06-13 CL CL2022001583A patent/CL2022001583A1/es unknown
- 2022-06-15 DO DO2022000125A patent/DOP2022000125A/es unknown
- 2022-06-16 JO JOP/2022/0154A patent/JOP20220154A1/ar unknown
- 2022-06-29 CO CONC2022/0009085A patent/CO2022009085A2/es unknown
- 2022-07-12 EC ECSENADI202254700A patent/ECSP22054700A/es unknown
-
2023
- 2023-05-29 CL CL2023001530A patent/CL2023001530A1/es unknown
- 2023-05-29 CL CL2023001531A patent/CL2023001531A1/es unknown
-
2024
- 2024-06-17 JP JP2024097435A patent/JP7781961B2/ja active Active
-
2025
- 2025-11-26 JP JP2025203483A patent/JP2026035699A/ja active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05279305A (ja) * | 1992-04-02 | 1993-10-26 | Ono Pharmaceut Co Ltd | 3′−アミノ−2′−ヒドロキシアセトフェノンの製造方法 |
| CN105330698A (zh) * | 2014-07-04 | 2016-02-17 | 南京明德新药研发股份有限公司 | 螺环芳基磷氧化物和硫化物 |
| US20170275302A1 (en) * | 2014-10-14 | 2017-09-28 | Alexander Pasternak | Inhibitors of the renal outer medullary potassium channel |
| US20190010167A1 (en) * | 2015-12-22 | 2019-01-10 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| CN109743875A (zh) * | 2016-06-10 | 2019-05-10 | 生命医药公司 | Menin-mll相互作用的抑制剂 |
| CN109689663A (zh) * | 2016-09-14 | 2019-04-26 | 詹森药业有限公司 | Menin-mll相互作用的螺二环抑制剂 |
| WO2018175746A1 (en) * | 2017-03-24 | 2018-09-27 | Kura Oncology, Inc. | Methods for treating hematological malignancies and ewing's sarcoma |
| WO2019060365A1 (en) * | 2017-09-20 | 2019-03-28 | Kura Oncology, Inc. | SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE |
| US20200216471A1 (en) * | 2017-09-20 | 2020-07-09 | Kura Oncology, Inc. | Substituted inhibitors of menin-mll and methods of use |
| WO2020069027A1 (en) * | 2018-09-26 | 2020-04-02 | Kura Oncology, Inc. | Treatment of hematological malignancies with inhibitors of menin |
Non-Patent Citations (5)
| Title |
|---|
| ANDREI V. KRIVTSOV, ET AL: "A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLLRearranged Leukemia", 《CANCER CELL》, vol. 36, 9 December 2019 (2019-12-09), pages 660 - 673 * |
| ASTA ZUKAUSKAITE, ET AL.: "Synthesis of 1, 5-diazaspiro[2.3]hexanes, a novel diazaspirocyclic system", 《TETRAHEDRON》, vol. 69, 26 February 2013 (2013-02-26), pages 3437 - 3443, XP029002886, DOI: 10.1016/j.tet.2013.02.065 * |
| COLUMBUS, OHIO, US REGISTRY[ONLINE]: "STN检索报告", 《STN REGISTRY》, 19 February 2014 (2014-02-19), pages 1 - 5 * |
| SUVI T. M. ORR,ET AL.: "One-pot synthesis of chiral azetidines from chloroaldehyde and chiral amines", 《TETRAHEDRON LETTERS》, vol. 52, 14 May 2011 (2011-05-14), pages 3618 - 3620, XP055073241, DOI: 10.1016/j.tetlet.2011.05.027 * |
| 芦金荣 等编著: "《化学药物》", vol. 2, 30 June 2013, 东南大学出版社, pages: 440 - 441 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12473295B2 (en) | 2019-12-19 | 2025-11-18 | Janssen Pharmaceutica Nv | Substituted straight chain spiro derivatives |
| WO2024046457A1 (en) * | 2022-09-02 | 2024-03-07 | Hutchmed Limited | Triazine compounds and uses thereof |
| CN120365200A (zh) * | 2025-04-18 | 2025-07-25 | 北京蓝博特科技有限公司 | 一种(s)-2-(3,5-二甲基苯基)吡咯烷盐酸盐的制备方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI878414B (zh) | 經取代之直鏈螺環接衍生物 | |
| KR20190032613A (ko) | (s)-7-(1-아크릴로일피페리딘-4-일)-2-(4-페녹시페닐)-4,5,6,7-테트라-하이드로피라졸로 [1,5-a] 피리미딘-3-카르복스아미드의 제조 및 그 용도 | |
| US20260125387A1 (en) | (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt | |
| WO2022237720A1 (en) | Combination therapies | |
| CN118845786A (zh) | 组合疗法 | |
| TW202313606A (zh) | 取代的苯基-1h-吡咯并[2,3-c]吡啶衍生物 | |
| CN110248946B (zh) | Menin-MLL相互作用的氮杂环庚烷抑制剂 | |
| TWI749518B (zh) | 哌嗪醯胺衍生物,其製備方法及其在醫藥上的用途 | |
| WO2022253289A1 (en) | Pyridazines or 1,2,4-triazines substituted by spirocyclic amines | |
| HK40113255A (en) | Substituted straight chain spiro derivatives | |
| HK40071760A (en) | Substituted straight chain spiro derivatives | |
| HK40117870A (en) | Combination therapies | |
| HK40118806A (en) | Combination therapies | |
| HK40100348A (en) | Combination therapies | |
| HK40098242A (en) | Combination therapies | |
| HK40117713A (en) | Compound useful for treating diseases such as cancer | |
| HK40101887A (en) | (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40071760 Country of ref document: HK |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |